Zacks Rating on Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) : 16 analysts are covering Edwards Lifesciences Corporation (EW) and their average rating on the stock is 1.53, which is read as a Buy. 11 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Edwards Lifesciences Corporation (EW) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Edwards Lifesciences Corporation (EW) : The most positive equity analysts on Edwards Lifesciences Corporation (EW) expects the shares to touch $140, whereas, the least positive believes that the stock will trade at $105 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $125.64 with an expected fluctuation of $10.2 from the mean.


Shares of Edwards Lifesciences Corp. rose by 3.91% in the last five trading days and 9.99% for the last 4 weeks. Edwards Lifesciences Corp. is up 15.44% in the last 3-month period. Year-to-Date the stock performance stands at 48.34%. Edwards Lifesciences Corporation (NYSE:EW): stock turned positive on Tuesday. Though the stock opened at $117.47, the bulls momentum made the stock top out at $117.92 level for the day. The stock recorded a low of $116.74 and closed the trading day at $117.16, in the green by 0.15%. The total traded volume for the day was 1,150,261. The stock had closed at $116.99 in the previous days trading.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.